Autobio Diagnostics Co Ltd
Autobio Diagnostics Co., Ltd. engages in the research and development, production, marketing, sale, and service of clinical diagnostic products in China and internationally. The company offers immunoassay, biochemistry, and microbiology products; reagents and instruments; and technical and support, and training services, as well as engages in biology research and development activities. Its immun… Read more
Market Cap & Net Worth: Autobio Diagnostics Co Ltd (603658)
Autobio Diagnostics Co Ltd (SHG:603658) has a market capitalization of $2.71 Billion (CN¥19.91 Billion) as of March 18, 2026. Listed on the SHG stock exchange, this China-based company holds position #8338 globally and #1566 in its home market, demonstrating a 1.28% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Autobio Diagnostics Co Ltd's stock price CN¥34.84 by its total outstanding shares 571424768 (571.42 Million).
Autobio Diagnostics Co Ltd Market Cap History: 2016 to 2026
Autobio Diagnostics Co Ltd's market capitalization history from 2016 to 2026. Data shows growth from $3.04 Billion to $2.71 Billion (0.76% CAGR).
Autobio Diagnostics Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Autobio Diagnostics Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.76x
Autobio Diagnostics Co Ltd's market cap is 0.76 times its annual revenue
0.72x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
2.85x
Autobio Diagnostics Co Ltd's market cap is 2.85 times its annual earnings
2.38x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $3.04 Billion | $980.22 Million | $349.76 Million | 3.10x | 8.70x |
| 2017 | $2.98 Billion | $1.40 Billion | $446.56 Million | 2.13x | 6.67x |
| 2018 | $2.76 Billion | $1.93 Billion | $562.57 Million | 1.43x | 4.91x |
| 2019 | $5.52 Billion | $2.68 Billion | $774.16 Million | 2.06x | 7.13x |
| 2020 | $8.36 Billion | $2.98 Billion | $747.79 Million | 2.81x | 11.18x |
| 2021 | $4.16 Billion | $3.77 Billion | $973.66 Million | 1.10x | 4.27x |
| 2022 | $4.75 Billion | $4.44 Billion | $1.17 Billion | 1.07x | 4.07x |
| 2023 | $4.44 Billion | $4.44 Billion | $1.22 Billion | 1.00x | 3.65x |
| 2024 | $3.40 Billion | $4.47 Billion | $1.19 Billion | 0.76x | 2.85x |
Competitor Companies of 603658 by Market Capitalization
Companies near Autobio Diagnostics Co Ltd in the global market cap rankings as of March 18, 2026.
Key companies related to Autobio Diagnostics Co Ltd by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #78 globally with a market cap of $191.37 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #154 globally with a market cap of $121.03 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #168 globally with a market cap of $113.17 Billion USD.
- Boston Scientific Corp (NYSE:BSX): Ranked #185 globally with a market cap of $105.26 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #78 | Abbott Laboratories | NYSE:ABT | $191.37 Billion | $110.71 |
| #154 | Stryker Corporation | NYSE:SYK | $121.03 Billion | $349.11 |
| #168 | Medtronic PLC | NYSE:MDT | $113.17 Billion | $88.44 |
| #185 | Boston Scientific Corp | NYSE:BSX | $105.26 Billion | $71.20 |
Autobio Diagnostics Co Ltd Historical Marketcap From 2016 to 2026
Between 2016 and today, Autobio Diagnostics Co Ltd's market cap moved from $3.04 Billion to $ 2.71 Billion, with a yearly change of 0.76%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥2.71 Billion | -1.64% |
| 2025 | CN¥2.76 Billion | -18.84% |
| 2024 | CN¥3.40 Billion | -23.45% |
| 2023 | CN¥4.44 Billion | -6.45% |
| 2022 | CN¥4.75 Billion | +14.10% |
| 2021 | CN¥4.16 Billion | -50.24% |
| 2020 | CN¥8.36 Billion | +51.48% |
| 2019 | CN¥5.52 Billion | +99.58% |
| 2018 | CN¥2.76 Billion | -7.17% |
| 2017 | CN¥2.98 Billion | -2.10% |
| 2016 | CN¥3.04 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Autobio Diagnostics Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.71 Billion USD |
| MoneyControl | $2.71 Billion USD |
| MarketWatch | $2.71 Billion USD |
| marketcap.company | $2.71 Billion USD |
| Reuters | $2.71 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.